Inventiva S.A. (0RNK.L)
0RNK.L Stock Price Chart
Explore Inventiva S.A. interactive price chart. Choose custom timeframes to analyze 0RNK.L price movements and trends.
0RNK.L Company Profile
Discover essential business fundamentals and corporate details for Inventiva S.A. (0RNK.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
30 Mar 2017
Employees
114.00
Website
https://www.inventivapharma.comCEO
Frederic Cren
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
0RNK.L Financial Timeline
Browse a chronological timeline of Inventiva S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 24 Mar 2026
Upcoming earnings on 25 Sept 2025
Earnings released on 23 May 2025
EPS came in at -€2.26 falling short of the estimated -€0.72 by -215.01%, while revenue for the quarter reached €6.46M, beating expectations by +5.72%.
Earnings released on 26 Sept 2024
EPS came in at -€0.94 surpassing the estimated -€1.22 by +22.69%, while revenue for the quarter reached €2.73M.
Earnings released on 22 May 2024
EPS came in at -€1.13 falling short of the estimated -€0.78 by -46.26%, while revenue for the quarter reached €16.54M, beating expectations by +17.52%.
Earnings released on 30 Jun 2023
EPS came in at -€1.31 falling short of the estimated -€1.17 by -12.35%, while revenue for the quarter reached €6.62M, beating expectations by +422.79%.
Earnings released on 31 Dec 2022
EPS came in at -€0.59 falling short of the estimated -€0.55 by -7.30%, while revenue for the quarter reached €15.42M, beating expectations by +1.46%.
Earnings released on 30 Jun 2022
EPS came in at -€0.72 surpassing the estimated -€0.86 by +16.15%, while revenue for the quarter reached €67.00K, missing expectations by -94.42%.
Dividend declared on 15 Mar 2022
A dividend of €0.29 per share was announced, adjusted to €0.29.
Earnings released on 31 Dec 2021
EPS came in at -€0.67 surpassing the estimated -€0.79 by +15.67%, while revenue for the quarter reached €4.06M, beating expectations by +31.05%.
Earnings released on 30 Jun 2021
EPS came in at -€0.60 surpassing the estimated -€0.77 by +22.31%, while revenue for the quarter reached €139.00K, beating expectations by +39.00%.
Earnings released on 31 Dec 2020
EPS came in at -€0.47 surpassing the estimated -€0.67 by +30.05%, while revenue for the quarter reached €211.00K, missing expectations by -94.79%.
0RNK.L Stock Performance
Access detailed 0RNK.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.